Scaffold Hopping-Guided Design of Novel PIM-1 Inhibitors with Anticancer Activities.

Yabing Xin, Qian Wu, Yitong Gao, Can Xiao, Qidong You, Zhengyu Jiang, Mengchen Lu

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yabing XinSchool of Pharmacy, Suzhou Medical College, Soochow University, Suzhou 215006, China.

Qian WuSchool of Pharmacy, Suzhou Medical College, Soochow University, Suzhou 215006, China.

Yitong GaoSchool of Pharmacy, Suzhou Medical College, Soochow University, Suzhou 215006, China.

Can XiaoJiang Su Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

Qidong YouJiang Su Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.ORCID 0000-0002-8587-0122

Zhengyu JiangJiang Su Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.ORCID 0000-0002-1671-1582

Mengchen LuSchool of Pharmacy, Suzhou Medical College, Soochow University, Suzhou 215006, China.ORCID 0000-0002-0947-2712

Funding

National Natural Science Foundation of China 2273768 and 82574254

6 · The paper itself

Abstract

PIM kinases, as members of the serine/threonine kinase family, regulate key cellular processes such as proliferation, apoptosis, and metabolism by phosphorylating multiple substrates, making them important therapeutic targets for cancer treatment. In this study, we reported a series of structurally novel PIM-1 kinase inhibitors based on a scaffold-hopping strategy. After multiple rounds of structural optimization, the highly active compound

Indexed as

Antineoplastic AgentsDrug DesignProtein Kinase InhibitorsProto-Oncogene Proteins c-pim-1AnimalsCell Line, TumorCell ProliferationHumansHydrogen BondingMolecular Docking SimulationMolecular StructureRatsStructure-Activity RelationshipAntineoplastic AgentsPIM1 protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-pim-1antitumoressentiality assessmentmolecular dockingPIM-1 inhibitorscaffold hopping

Identifiers

PMID41752530

DOI10.3390/molecules31040753

PMCPMC12943290

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.